Selection of a novel DNA aptamer against OFA/iLRP for targeted delivery of doxorubicin to AML cells

The standard treatment for most acute myeloid leukemia (AML) is chemotherapy, which is often associated with severe adverse effects. One strategy to reduce the adverse effects is targeted therapy that can selectively deliver anticancer drugs to tumor cells. Immature laminin receptor protein (OFA/iLR...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2019-05, Vol.9 (1), p.7343-7343, Article 7343
Hauptverfasser:	An, Yacong, Hu, Yan, Li, Xundou, Li, Zhaoyi, Duan, Jinhong, Yang, Xian-Da
Format:	Artikel
Sprache:	eng
Schlagworte:	13/31 14/19 38/23 38/77 631/67/1059/602 631/67/1990/283/1897 Acute myeloid leukemia Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacology Antineoplastic drugs Antitumor agents Aptamers Aptamers, Nucleotide - metabolism Chemotherapy Cross-reactivity Cytotoxicity Deoxyribonucleic acid DNA DNA structure Doxorubicin Doxorubicin - administration & dosage Doxorubicin - pharmacology Drug Carriers - metabolism Drug Delivery Systems HL-60 Cells Humanities and Social Sciences Humans Laminin Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - metabolism multidisciplinary Myeloid leukemia Oligonucleotides Ovalbumin Receptors, Laminin - metabolism Ribosomal Proteins - metabolism Science Science (multidisciplinary) Side effects Trypsin Tumor cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!